Dr. Reddy’s Q2 and H1 FY17 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Dr. Reddys Labs (RDY) Reports Q2 EPS of $0.27
October 25, 2016 7:24 AM EDTDr. Reddys Labs (NYSE: RDY) reported Q2 EPS of $0.27, versus $0.63 reported last year. Revenue for the quarter came in at $539 billion, versus $599 billion reported last year.
Commenting on the results, Co-chairman and CEO, G V Prasad said, All our major businesses have shown... More
